Welcome to our dedicated page for Dlh Holdings news (Ticker: DLHC), a resource for investors and traders seeking the latest updates and insights on Dlh Holdings stock.
DLH Holdings Corp. (DLHC) provides technology-driven business process outsourcing and program management solutions for federal health and defense agencies. This news hub offers investors and stakeholders centralized access to official corporate developments and strategic initiatives.
Track all essential updates including earnings reports, federal contract awards, and technology partnerships shaping DLH's position in government health services. Our repository features verified press releases on public sector acquisitions, health IT innovations, and defense logistics programs without promotional bias.
Key updates cover DLH's work with agencies like the Department of Veterans Affairs and Defense Health Agency, emphasizing their digital transformation initiatives in telehealth and analytics. Users gain insights into operational milestones through primary source documents and objective reporting.
Bookmark this page for streamlined monitoring of DLHC's evolving role in federal healthcare solutions. Check regularly for new developments affecting government contracting strategies and public health program management.
DLH Holdings Corp. (NASDAQ: DLHC) has announced that the Department of Veterans Affairs' Consolidated Mail Order Pharmacy (CMOP) program achieved the highest customer satisfaction rating in J.D. Power's 2022 U.S. Pharmacy Study. CEO Zach Parker emphasized the program's ability to maintain this satisfaction despite challenges like labor market issues and inflation. The study is based on thousands of customer responses and reinforces DLH's commitment to providing essential services to Veterans.
DLH Holdings Corp. (NASDAQ: DLHC) has secured an Indefinite Delivery/Indefinite Quantity (ID/IQ) contract with the Department of Veteran Affairs (VA) aimed at enhancing healthcare innovations. This contract, part of the Accelerating VA Innovation and Learning (AVAIL) initiative, features a five-year base period with a ceiling of $650 million across 17 competitors. DLH will utilize its expertise in digital health tools and advanced technologies to support Veterans with improved care solutions.
DLH Holdings Corp. (NASDAQ: DLHC) reported fiscal Q3 2022 results with revenue of $66.4 million, an 8% increase year-over-year. Earnings rose to $4.9 million, or $0.34 per diluted share, up from $2.9 million or $0.21 per diluted share in Q3 2021. The operating margin improved to 10.7% from 8.0%. Debt was reduced to $28.5 million, down from $37.5 million. Contract backlog stood at $509.7 million as of June 30, 2022. The company secured two major contracts with federal agencies, enhancing its growth prospects for fiscal 2023.
DLH Holdings Corp. (NASDAQ: DLHC) is set to release its fiscal third-quarter financial results on August 2, 2022. The results will cover the period ended June 30, 2022. Following the financial release, a conference call is scheduled for August 3, 2022, at 10:00 a.m. ET, where senior management will discuss the results and operational trends. Interested parties can participate via phone or access the presentation materials on the Investor Relations section of the DLH website. A digital recording of the call will be available afterward.
DLH Holdings Corp. (NASDAQ: DLHC) announced that its subsidiary, Social & Scientific Systems, Inc., secured an Indefinite Delivery/Indefinite Quantity (ID/IQ) contract with the National Cancer Institute (NCI). This contract allows DLH to support cancer research in various task areas including study management and biospecimen activities, with a potential ceiling of $320 million over ten years. The contract replaces previous NCI agreements and positions DLH to enhance its public health missions, particularly in cancer prevention and research.
DLH Holdings Corp. (NASDAQ: DLHC) announced a new contract with the National Institute of Environmental Health Sciences (NIEHS) to provide statistical, mathematical, and computational support. This award, valued at approximately $13 million, spans one year with four additional one-year options. DLH will deliver software programming, research support, and data visualization focusing on areas like carcinogenesis and toxicology. The contract continuation highlights DLH's strong partnership with NIEHS, showcasing its expertise in public health and scientific research.
DLH Holdings Corp. (NASDAQ: DLHC) announced an award of an Indefinite Delivery/Indefinite Quantity (ID/IQ) contract with the Department of Defense. This contract involves health-related research and support services, focusing on medical simulation, infectious diseases, and battlefield healthcare. It has a potential total ceiling of $10 billion over five years, with task orders to be competed as needed. The initiative aligns with DLH's expertise in digital transformation and medical research, positioning the company to enhance military health readiness.
DLH Holdings Corp. (NASDAQ: DLHC) reported a strong fiscal second quarter for 2022, achieving revenue of $108.7 million, a significant increase from $61.5 million in Q2 2021. This growth was primarily driven by two FEMA contracts worth approximately $39.8 million. Earnings were $7.2 million or $0.50 per share, up from $2.6 million or $0.19 per share year-over-year. The company reduced term debt to $37.5 million and reported a backlog of $554.7 million. Management remains optimistic about future opportunities and ongoing debt repayment.
DLH Holdings Corp. (NASDAQ: DLHC) announced on April 21, 2022, the awarding of a new contract to provide ongoing support to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This contract has a total value of approximately $14 million and includes a base period of one year with four optional extensions. DLH will assist in epidemiological research, statistical programming, and data analysis related to chronic diseases. The company emphasizes its commitment to improving public health through its partnership with NIDDK.
